title: Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma.
abstract: The aim of this study was to investigate the efficacy and safety of combination chemotherapy with weekly paclitaxel and 5-fluorouracil (5-FU) as first-line treatment in patients with advanced or recurrent gastric carcinoma. A total of 65 patients were treated with the following regimen, administered every 28 days; 5-FU 600 mg/m2 by 24-hour continuous infusion from days 1 through 5, and weekly paclitaxel 80 mg/m2 by 3-hour intravenous infusion on days 8, 14, and 21. A total of 272 cycles were conducted with a median of 4 (2-13) cycles per case. Out of 57 patients with measurable disease by RECIST criteria, there were 2 complete responses (3.5%), 20 partial responses (35.1%) and 25 cases with stable disease (43.9%). The overall response rate was 38.6% (95%CI: 26.0-51.2%). The median survival time and 1-year survival rates were 329 days and 47.4%, respectively. Both hematologic and non-hematologic toxicities were well tolerated.
authors.affiliation: Department of Surgery, Hiroshima City Hospital, Hiroshima, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ninomiya
authors.forename: K
authors.initials: K
authors.lastname: Kondo
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: N
authors.initials: N
authors.lastname: Hirabayashi
authors.forename: H
authors.initials: H
authors.lastname: Kojima
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Kawamura
authors.forename: T
authors.initials: T
authors.lastname: Ando
authors.forename: N
authors.initials: N
authors.lastname: Musha
authors.forename: H
authors.initials: H
authors.lastname: Konno
authors.forename: N
authors.initials: N
authors.lastname: Nagata
authors.forename: H
authors.initials: H
authors.lastname: Usuki
authors.forename: Y
authors.initials: Y
authors.lastname: Miyashita
authors.forename: K
authors.initials: K
authors.lastname: Oba
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.forename: J
authors.initials: J
authors.lastname: Sakamoto
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D005472:Fluorouracil